Le Lézard
Classified in: Health, Business
Subject: CON

Xandar Kardian joins Innovators' Network at American Heart Association Center for Health Technology & Innovation


American Heart Association consortium advances development of evidence-based health tech solutions

TORONTO, Oct. 6, 2022 /PRNewswire/ -- Xandar Kardian, a Toronto-based company that develops contactless health monitoring solutions, has joined the American Heart Association Center for Health Technology & Innovation's (the Center) Innovators' Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.

The Innovators' Network is a consortium that connects entrepreneurs, providers, researchers and payers. Innovators' Network members also have access to the Association's digital guidelines, recommendations, and best-in-class science as they develop digital healthcare technologies. Members collaborate with the Center in different ways, including the building of models for clinical outcome studies, lowering the significant cost of developing those studies independently, helping connect the science to technology, and providing evidence that a digital platform improves healthcare outcomes ? a key concern for providers and payers.

"The Center aims to advance the rapid, efficient, and effective development of healthcare technology," said Eric Peterson, M.D., M.P.H., volunteer chair of the American Heart Association's Health Tech Advisory Group for the Center and Vice Provost and Senior Associate Dean for Clinical Research at University of Texas Southwestern. "Joining the Innovators' Network gives members the opportunity to leverage the consortium and work toward broadening and deepening their engagement in this arena."

"We are absolutely thrilled to be joining the Innovators' Network," Sam Yang, Co-founder and Managing Director of Xandar Kardian said. "The Innovator's Network opens opportunities to connect with other Network members and provides access to the Association's science and guidelines as we develop innovative tools focused on improving outcomes. Joining the Network allows us to work toward our goal to revolutionize patient care and ultimately save lives."

About Xandar Kardian

Xandar Kardian joins the Innovators' Network bringing with them the XK300, a medical device that uses radar for detecting resting heart rate, respiratory rate, motion, and presence. The device uses UWB radar to detect micromovements of the human body, keeping health care workers updated on their patients' vital signs autonomously.

Xandar Kardian is focused on deploying reliable and high accuracy security and healthcare solutions worldwide. Xandar Kardian elevates motion sensor technology to the next level, incorporating radar sensors that monitor vital signs via resting heart rate (RHR) and respiratory rate (RR), providing insights into occupant motion, location, and vital sign reading.

MEDIA CONTACT:

Ruben Marinbach
Account Director
GreenRoom Agency
[email protected]
305-347-1787 Ext. 305

SOURCE Xandar Kardian


These press releases may also interest you

at 07:40
The "Global Weight Loss Drugs Market: Analysis By Product Type, By Drug Type, By Distribution Channel, By End User, By Region, Size and Trends with Impact of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's...

at 07:35
Arrowhead Pharmaceuticals, Inc. today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company's proprietary Targeted RNAi Molecule...

at 07:35
Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share Related to Acquired IPR&D and...

at 07:30
During an awards ceremony to present the 2024 list of Best Workplacestm in Canada, Great Place to Work® announced the 50 Best Workplacestm in Canada with 100-999 employees....

at 07:05
At the ESCMID Global 2024 conference, Bruker is enhancing its innovative diagnostic solutions in microbial identification, antimicrobial susceptibility testing (AST), early sepsis diagnostics, and other infectious disease assays. Simplifying...

at 07:00
Bristol Myers Squibb today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo® (nivolumab) in combination with cisplatin and gemcitabine for the...



News published on and distributed by: